<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis and biomarkers of cardiovascular disease in patients with HIV</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis and biomarkers of cardiovascular disease in patients with HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis and biomarkers of cardiovascular disease in patients with HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Judith S Currier, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rajesh T Gandhi, MD, FIDSA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H10000541"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>As people with HIV have a near normal lifespan with treatment, cardiovascular disease has emerged as an important cause of morbidity and mortality. Even with effective antiretroviral therapy (ART), people with HIV have a higher risk of myocardial infarction and cardiovascular death than age-matched uninfected controls. The excess risk of myocardial infarction in people with HIV remains elevated compared to the general population, despite improvements in HIV treatment [<a href="#rid1">1</a>]. Traditional risk factors, such as smoking, hypertension, and dyslipidemia, contribute substantially to this higher risk [<a href="#rid2">2</a>], but there is also evidence that HIV infection and, to a lesser extent, its treatment are directly linked to atherogenesis, endothelial dysfunction, and coagulation abnormalities, probably through inflammation and immune dysregulation.</p><p>Measures of subclinical cardiovascular disease and the pathogenesis of atherosclerosis in patients with HIV are discussed here. The epidemiology of cardiovascular morbidity and traditional risk factors and the management of dyslipidemia and cardiovascular risk in patients with HIV are addressed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3739.html" rel="external">"Management of cardiovascular risk (including dyslipidemia) in patients with HIV"</a>.)</p><p class="headingAnchor" id="H10000548"><span class="h1">SUBCLINICAL ATHEROSCLEROSIS</span><span class="headingEndMark"> — </span>Cardiovascular disease has emerged as an important cause of death in patients with HIV, as illustrated by clinical studies evaluating such hard endpoints as stroke or myocardial infarctions (see  <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV"</a>). However, people with HIV, especially those who are younger, have overall low short-term cardiovascular risk and few events. Therefore, many clinical studies rely upon surrogate markers to indirectly assess the burden of cardiovascular disease. These studies have generally demonstrated an increased prevalence of subclinical atherosclerosis in individuals with HIV compared to those without. Such measurements include intima media thickness (IMT) and intraluminal arterial plaque as assessed by ultrasound and evaluation of coronary artery calcification and plaque by computed tomography (CT). These measurements have been moderately associated with coronary atherosclerosis and the future risk of a cardiovascular event in studies of uninfected adults [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/16307.html" rel="external">"Overview of possible risk factors for cardiovascular disease", section on 'Arterial intima-media thickness'</a> and  <a class="medical medical_review" href="/z/d/html/16307.html" rel="external">"Overview of possible risk factors for cardiovascular disease", section on 'Coronary artery calcification'</a>.)</p><p>Evidence of increased subclinical atherosclerosis among elite controllers with HIV compared with uninfected controls has also been observed, suggesting that an increased risk of atherosclerosis can occur in the absence of antiretroviral therapy (ART), detectable viremia, or overt immunodeficiency [<a href="#rid4">4-6</a>].</p><p class="headingAnchor" id="H1396134202"><span class="h2">Intima media thickness</span><span class="headingEndMark"> — </span>Most, but not all studies of IMT of the carotid artery and coronary arteries in asymptomatic adults have found an increase in measurement with HIV infection [<a href="#rid4">4,7-16</a>]. In a meta-analysis of observational studies evaluating subclinical atherosclerosis in patients with HIV, the following observations were noted [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Among the 13 studies that compared carotid IMT in patients with HIV versus those without, all except for two reported a trend towards higher carotid IMT with HIV. However, the weighted mean difference between patients with HIV and patients without HIV was very small, 0.04 mm (95% CI 0.02-0.06). Moreover, there was significant statistical and clinical heterogeneity between the studies, including differences in measurement technique and underlying traditional cardiovascular risk factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no difference in the weighted means of carotid IMT measurements from 12 studies comparing patients with HIV and with or without protease inhibitor exposure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was evidence of selection bias, with small studies showing an effect of HIV infection and larger studies showing lack of difference.</p><p></p><p>Despite the limitations of the meta-analysis, several subsequent large observational studies supported its findings and reported even larger increases in IMT with HIV infection [<a href="#rid4">4,8</a>]. The association between HIV infection and IMT may be modulated by age. In a study of over 1700 patients with HIV, carotid IMT was higher compared with age-matched uninfected controls among individuals aged 6 to 29 years but was similar to controls among adults 30 years and older, among whom IMT correlated more strongly with traditional risk factors [<a href="#rid17">17</a>]. However, other studies have noted higher IMT among patients with HIV, even when adjusted for age [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H1555533145"><span class="h3">Effect of antiretroviral therapy on intima media thickness</span><span class="headingEndMark"> — </span>The effect of ART on IMT appears to vary by agent. As an example, in a randomized trial, <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">atazanavir</a> was associated with a slower rate of progression of carotid IMT compared with <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">darunavir</a>; this difference was hypothesized to be related to the fact that atazanavir increases bilirubin, which may exert an antioxidant effect that slows the progression of atherosclerosis [<a href="#rid18">18</a>]. The effect of <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">raltegravir</a> was intermediate. An observational study of 102 ART-naïve patients demonstrated comparable progression of carotid IMT over two years among those who started on <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">tenofovir alafenamide</a>/<a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">emtricitabine</a> plus either raltegravir, <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">elvitegravir</a>/<a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">cobicistat</a>, or <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H1396134208"><span class="h2">Coronary artery calcification and plaque</span><span class="headingEndMark"> — </span>Studies suggest that individuals with HIV may not have a greater burden of coronary artery calcification than uninfected patients after controlling for traditional cardiovascular risk factors but are more likely to have non-calcified atherosclerotic plaque, which may be more likely to rupture.</p><p>Additional studies have evaluated coronary artery calcification, which is detected by CT, in patients with HIV. In the meta-analysis discussed above, there was no difference in coronary artery calcification between people with HIV and people without HIV in the pooled results from five studies [<a href="#rid7">7</a>]. However, some but not all [<a href="#rid20">20</a>] subsequent studies using CT angiography to assess overall plaque burden have reported a higher prevalence among people with HIV compared to those without HIV with similar Framingham risk scores [<a href="#rid21">21-25</a>]. As an example, in a multicenter observational study of 450 HIV-infected and 309 uninfected men who have sex with men between the ages of 40 and 70 years, HIV infection was associated with a higher prevalence of plaque in any coronary segment, as detected by CT angiography, even after adjustment for age, race, and traditional cardiovascular risk factors (prevalence ratio [PR] 1.13, 95% CI 1.04-1.23) [<a href="#rid24">24</a>]. Specifically, individuals with HIV had a higher adjusted prevalence and extent of non-calcified plaque, which was associated with advanced age, lower nadir CD4 cell count, and longer duration of ART. The majority of the men with HIV in this study were on ART. Statin therapy appears to ameliorate this finding. In a prospective study of individuals with HIV, treatment with <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> was associated with improvement in non-calcified plaque volume [<a href="#rid26">26</a>].</p><p>The prevalence of plaque among people with HIV with estimated low to moderate ASCVD risk was reported from a baseline analysis of the CT substudy in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), a large, ongoing primary prevention trial of statin therapy among people with HIV [<a href="#rid27">27</a>]. Plaque was reported in nearly half of the participants. Although luminal obstruction of more than 50 percent was rare (3 percent), vulnerable plaque was observed in 23 percent of patients. Follow-up data from this cohort will further elucidate the factors associated with progression of plaque. </p><p class="headingAnchor" id="H25650733"><span class="h1">PATHOGENESIS OF VASCULAR DISEASE</span><span class="headingEndMark"> — </span>The development of atherosclerosis that underlies cardiovascular disease and events is a complicated and multifactorial process that involves inflammation and immune dysregulation, endothelial dysfunction, and plaque rupture, as well as the traditional risk factors of hypertension, diabetes, dyslipidemia, and smoking. (See  <a class="medical medical_review" href="/z/d/html/13603.html" rel="external">"Pathogenesis of atherosclerosis"</a>.)</p><p>This section discusses markers of inflammation, endothelial function, and coagulation that have been associated both with HIV infection as well as with progression to atherosclerosis or cardiovascular events in the general population. Although a number of abnormalities in soluble and cellular markers have been associated with cardiovascular disease in patients with HIV, there are none that have been validated yet for clinical use.</p><p>The prevalence of traditional risk factors in patients with HIV is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV", section on 'Traditional risk factors'</a>.)</p><p class="headingAnchor" id="H1593221"><span class="h2">Inflammation</span><span class="headingEndMark"> — </span>Inflammation plays a pivotal role in the development of atherosclerosis in general and is an area of active research with regards to HIV infection. Active inflammation may adversely affect endothelial cells and promote a prothrombotic environment that leads to atherosclerosis and plaque rupture. HIV infection has been linked to several markers of inflammation, including C-reactive protein (CRP) and interleukin (IL)-6, which in turn have been associated with cardiovascular events.</p><p class="headingAnchor" id="H111728149"><span class="h3">Imaging studies</span><span class="headingEndMark"> — </span>Through positron emission tomography (PET) imaging, arterial inflammation can be detected by increased uptake of a radiolabeled glucose analog, fluorodeoxyglucose (FDG), in blood vessels. In one study of 27 patients with HIV (mean age 52 years) on antiretroviral therapy (ART) and without known cardiac disease, PET imaging was performed and compared with the findings in uninfected patients who underwent PET imaging for other reasons [<a href="#rid28">28</a>]. Arterial inflammation in the aorta among patients with HIV was higher compared with uninfected patients who also had no known cardiac disease and were matched by age, sex, and Framingham risk score but was similar to that seen in sex-matched uninfected patients (mean age, 69 years) who had known atherosclerotic disease. Although aortic inflammation was not associated with levels of CRP and D-dimer, it did correlate with sCD163, a soluble marker of monocytes and macrophage that has been associated with atherosclerosis in uninfected populations.</p><p class="headingAnchor" id="H111728157"><span class="h3">Soluble markers</span></p><p class="headingAnchor" id="H1593279"><span class="h4">C-reactive protein</span><span class="headingEndMark"> — </span>CRP is the most extensively studied of numerous inflammatory biomarkers potentially linked to underlying atherosclerosis in the general population, among whom elevations in CRP are associated with an increased risk of cardiovascular events independent of traditional risk factors. (See  <a class="medical medical_review" href="/z/d/html/1484.html" rel="external">"C-reactive protein in cardiovascular disease"</a>.)</p><p>HIV infection has been associated with increased CRP levels when compared with uninfected controls [<a href="#rid29">29</a>]. Furthermore, in a study of 922 patients with HIV followed for five years, a high CRP was independently associated with increased overall mortality [<a href="#rid30">30</a>]. With regards to the specific morbidity of cardiovascular disease, the association between CRP levels and myocardial infarction risk in patients with HIV was evaluated in a study of a large hospital database that included 487 patients with HIV and 69,870 patients without HIV [<a href="#rid31">31</a>]. High CRP (any value exceeding the upper limit of normal of the standard assay or any value in the highest quantile of the high sensitivity CRP assay) was found more frequently among patients with HIV (59 versus 39 percent). In an adjusted model controlling for age, sex, race, hypertension, diabetes and dyslipidemia, the risk for acute myocardial infarction was increased more than fourfold among patients with HIV infection and increased CRP when compared with patients with neither risk factor. There was no association between CRP level and HIV viral load or CD4 cell count, but protease inhibitor use was associated with high CRP levels.</p><p>The effect of ART in general on CRP is unclear, with some studies showing an increase [<a href="#rid32">32</a>] and others showing a decrease [<a href="#rid33">33</a>]. Changes in CRP level may depend on the particular agent used [<a href="#rid34">34-36</a>]. In a study of 244 patients who had been randomly assigned to initiate one of four ART regimens, increases in CRP at weeks 24 and 96 were observed with regimens containing <a class="drug drug_general" data-topicid="9010" href="/z/d/drug information/9010.html" rel="external">abacavir-lamivudine</a>, particularly when used with <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a>, in contrast to stable levels with tenofovir-emtricitabine or boosted <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">atazanavir</a> [<a href="#rid37">37</a>]. This finding was notable because of an apparent increase in myocardial infarction risk seen with <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> in a large cohort of patients with HIV (see  <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV", section on 'Abacavir'</a>). However, this study did not analyze the association of such changes in CRP with cardiovascular events, and in fact, the two participants who experienced a myocardial infarction during the study period were receiving tenofovir-emtricitabine and efavirenz. In other studies among patients who had been on long-term ART, changes in biomarkers of inflammation were more likely to be related to personal factors such as smoking and obesity than ART [<a href="#rid38">38</a>].</p><p>It is unclear whether the association between CRP and cardiovascular events in individuals with HIV differs from that among the uninfected population [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H1593286"><span class="h4">Interleukin-6</span><span class="headingEndMark"> — </span>Increased levels of the proinflammatory cytokine IL-6 are thought to have a direct causal role in the development of coronary heart disease among the general population (see  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease", section on 'Interleukin-6'</a>) and have been observed in patients with HIV infection, particularly with more advanced disease. In a study of 1525 veterans with HIV, there was no overall difference in prevalence of increased IL-6 compared with 843 uninfected controls after controlling for age and race [<a href="#rid40">40</a>]. However, there was a greater association with increased IL-6 levels compared with the uninfected in the setting of an HIV viral load ≥500 copies/mL (odds ratio [OR] 1.54, 95% CI 1.14-2.09) or a CD4 cell count &lt;200 cells/microL (OR 2.25, 95% CI 1.60-3.16). Furthermore, in post hoc analyses of participants in the SMART trial, which evaluated ART continuation versus treatment interruption based on CD4 cell count, increased levels of IL-6 were associated with HIV RNA viremia, cardiovascular events, and all-cause mortality [<a href="#rid41">41,42</a>]. A subsequent small study suggested that elevations in IL-6 were associated with endothelial dysfunction as reflected by changes in small artery elasticity and endothelial adhesion molecules [<a href="#rid43">43</a>]. Finally, in a post hoc analysis of samples from two completed HIV trials, IL-6 was a stronger predictor of cardiovascular events than D-dimer [<a href="#rid44">44</a>].</p><p>In the cross-sectional CT angiography study noted above from the REPRIEVE trial, LpPLA2 and IL-6 levels were associated with the presence of coronary plaque after adjustment for traditional risk factors and CD4 count and HIV RNA.</p><p class="headingAnchor" id="H7498409"><span class="h2">Cellular activation</span></p><p class="headingAnchor" id="H7498416"><span class="h3">T cell activation</span><span class="headingEndMark"> — </span>Activation of T cells is a hallmark of HIV infection and levels of activated CD4 and CD8 T cells have been linked to rates of disease progression. During effective ART, levels of activation fall, but not back to pre-HIV levels in most patients, at least during the first few years of treatment. Studies examining the relationship between T-cell activation and atherosclerosis in HIV infection have yielded inconsistent results. Cross-sectional studies have demonstrated associations between the proportion of activated and senescent CD8 T cells and carotid intima media thickness and carotid lesions [<a href="#rid45">45-48</a>].</p><p class="headingAnchor" id="H7498422"><span class="h3">Monocyte activation</span><span class="headingEndMark"> — </span>Several lines of evidence suggest that monocyte activation may contribute to the development of atherosclerosis in HIV [<a href="#rid28">28,45,49-54</a>]. Soluble CD163, the extracellular component of the hemoglobin-haptoglobin receptor CD163, is released from activated monocytes and macrophages during inflammation. Both aortic inflammation and soft plaque volume in patients with HIV have correlated with sCD163 [<a href="#rid28">28,49</a>]. In addition, sCD14 levels were associated with progression of carotid intima media thickness (IMT) in a small study [<a href="#rid50">50</a>]. Several studies have reported increased levels of innate immune activation during treated HIV infection and associations between cellular measures of activated monocyte populations and carotid IMT in HIV [<a href="#rid45">45,51,52</a>]. Additionally, progression of coronary-artery calcium has been associated with higher frequencies of activated monocytes, but not tissue factor expression, T-cell activation, or senescence phenotype [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H1643344862"><span class="h2">Endothelial dysfunction</span></p><p class="headingAnchor" id="H10000562"><span class="h3">Arterial dynamics</span><span class="headingEndMark"> — </span>In a clinical trial of treatment-naïve subjects randomly assigned to initiate various ART regimens, there was a rapid and significant improvement in flow-mediated dilation of the brachial artery, a measure of endothelial function, during the first 24 weeks of therapy [<a href="#rid55">55</a>]. This improvement in flow-mediated dilation was seen regardless of regimen, suggesting that suppression of HIV, and not the specific drugs themselves, led to improved endothelial function [<a href="#rid56">56</a>]. Another study used noninvasive measurement of radial pulse waveforms to assess large and small artery elasticity in 32 treatment-naïve individuals with HIV and 30 individuals without HIV [<a href="#rid57">57</a>]. After adjusting for risk factors, including the Framingham 10-year cardiovascular disease risk score, those with HIV infection demonstrated significantly less elasticity in both large and small arteries when compared with the uninfected group. These data suggest that chronic HIV infection, independent of its pharmacologic treatment, induces alterations of endothelial function.</p><p>However, there is evidence for endothelial dysfunction in patients with HIV on therapy as well. Increased pulse wave velocity, which may be an early marker for atherosclerosis, has been noted in two small studies of patients with HIV taking ART compared with uninfected controls [<a href="#rid58">58,59</a>]. Cumulative duration of ART exposure was associated with an incremental increase in velocity, supporting a role of HIV therapy in the pathogenesis of endothelial dysfunction.</p><p>Certain antiretroviral agents may be more highly associated with abnormal endothelial function than others. In uninfected individuals, the use of <a class="drug drug_general" data-topicid="8558" href="/z/d/drug information/8558.html" rel="external">indinavir</a> was associated with endothelial dysfunction, independent of drug-induced alterations in blood pressure or lipid profiles [<a href="#rid60">60</a>]. However, in contrast to the dramatic impairment seen with indinavir, <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">atazanavir</a> and lopinavir did not induce endothelial dysfunction in 18 healthy subjects in another small study [<a href="#rid61">61</a>]. These data suggest that any endothelial dysfunction related to protease inhibitors is drug specific and not class specific.</p><p>One small study of 61 patients on ART suggested that <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> may be associated with endothelial dysfunction as assessed by flow-mediated dilation, which may underlie the observed increased risk of myocardial infarction among abacavir-treated patients [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H63640431"><span class="h3">Plasma markers of endothelial function</span><span class="headingEndMark"> — </span>In a longitudinal study of patients newly infected with HIV, measures of endothelial activation (ICAM-1 and VCAM-1) were increased early after HIV acquisition [<a href="#rid63">63</a>]. Additionally, in the absence of ART during chronic infection, plasma VCAM-1 levels were independently associated with time to HIV progression or death.</p><p>In a retrospective cohort study of 56 patients with HIV starting an ART regimen based on either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor, serum markers of endothelial dysfunction (eg, monocyte chemoattractant protein, P-selectin, vascular cell adhesion molecule, and von Willebrand factor) declined similarly with either treatment approach [<a href="#rid64">64</a>]. By contrast, increased levels of these markers were observed at baseline and 3, 6, and 12 months of follow-up in a control cohort of 10 untreated patients with HIV and CD4 cell counts &gt;500 cells/mm<sup>3</sup>. Compared with patients with HIV, healthy controls had significantly lower levels of all measured markers at every time point.</p><p>Similarly, in a subset analysis of patients with HIV randomly assigned to start ART immediately (n = 134) or to delay ART initiation until warranted by HIV disease progression (n = 114), the levels of asymmetric dimethylarginine (ADMA), an inhibitor of the nitric oxide synthase pathway that reflects endothelial dysfunction and may be an independent risk factor for cardiovascular disease, changed more favorably after 12 months with immediate ART administration [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/z/d/html/16307.html" rel="external">"Overview of possible risk factors for cardiovascular disease", section on 'Asymmetrical dimethylarginine'</a>.)</p><p>However, other studies have shown that antiretroviral medications also contribute to aberrations in levels of markers of endothelial function, such as soluble endothelial adhesion molecules [<a href="#rid60">60,66-69</a>]. In one study, plasma P-selectin and t-PA were measured in 60 patients on ART and 60 treatment-naïve patients. Significantly higher levels of both markers were found in those taking ART [<a href="#rid66">66</a>].</p><p>These clinical studies of altered endothelial function in HIV infection are supported by in vitro and animal studies. A preliminary report from a study examining aortic tissue from the simian immunodeficiency virus (SIV) macaque model reported focal endothelial proliferation and infiltration of monocytes, T lymphocytes, and platelets in three of the four SIV infected animals, compared with none of the uninfected controls [<a href="#rid70">70</a>]. In addition, there were reduced levels of factors that promote an antithrombotic environment in the endothelium (Krüppel-like factor 2 [KLF2] and endothelial nitric oxide synthase). In an AIDS murine model, vascular smooth muscle tone is reduced as early as the first week after retroviral infection, suggesting vascular dysfunction precedes the onset of significant immunodeficiency [<a href="#rid71">71</a>]. This effect may be mediated by vascular endothelial nitric oxide dysregulation and prostacyclin-induced vasodilation [<a href="#rid72">72</a>]. In vitro studies have demonstrated that HIV-associated proteins, such as gp120 and Tat (transactivator of viral replication), are toxic to vascular or cardiac cell lines [<a href="#rid73">73,74</a>].</p><p class="headingAnchor" id="H10000576"><span class="h2">Abnormalities of coagulation</span><span class="headingEndMark"> — </span>In addition to endothelial dysfunction, there is also evidence of a dysregulation of coagulation and fibrinolysis, which have been linked to cardiovascular disease in the general population. </p><p>Several studies have described increased plasma levels of endothelial cell products, including von Willebrand factor and soluble thrombomodulin, and the fibrin degradation product D-dimer in those living with HIV, and these levels are noted to inversely correlate with CD4 counts [<a href="#rid40">40,75-77</a>]. A positive correlation has also been noted between HIV viral load and prothrombin fragment in 90 individuals with HIV (mean age 38 ± 9 years, mean CD4 216 ± 198) not receiving ART, which suggests that increasing levels of viremia may increase the risk for thrombosis [<a href="#rid78">78</a>].</p><p>Moreover, increased D-dimer levels in the setting of treatment interruption and increased fibrinogen levels have been associated with increased mortality in patients with HIV [<a href="#rid30">30,41</a>]. Additionally, in a case-control study of patients with HIV who had experienced a cardiovascular event (n = 52) or had not (n = 104), D-dimer was independently associated with cardiovascular event risk [<a href="#rid79">79</a>].</p><p>However, not all changes in markers of coagulation in the setting of HIV infection suggest a hypercoagulable state. In a study of 278 males with HIV, levels of antithrombin were higher and levels of a functional measure of thrombin generation were lower compared with 39 uninfected controls [<a href="#rid80">80</a>].</p><p>Furthermore, it is unclear what the impact of ART is on coagulation. One study of 1131 patients with HIV and 281 controls found that protease inhibitor use was associated with higher fibrinogen levels (with the strongest associations for <a class="drug drug_general" data-topicid="8558" href="/z/d/drug information/8558.html" rel="external">indinavir</a> and <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a>), whereas non-nucleoside reverse transcriptase inhibitor use was associated with lower fibrinogen levels [<a href="#rid81">81</a>].</p><p>Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) may play a role in the pathogenesis of atherosclerosis in HIV infection [<a href="#rid82">82</a>]. Chronic immune stimulation increases TF expression on the surface of monocytes. In a study of 121 adults with HIV, higher concentrations of TF were associated with subclinical atherosclerosis (assessed by carotid intima media thickness) and correlated with longer duration of ART and lower nadir CD4 counts [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H10000612"><span class="h2">Other factors associated with atherosclerosis</span></p><p class="headingAnchor" id="H10000627"><span class="h3">Viral co-infection</span><span class="headingEndMark"> — </span>The presence of ongoing inflammation secondary to the presence of other chronic viral infections may also promote the development of atherosclerosis and subclinical cardiovascular disease in patients with HIV.</p><p>Asymptomatic infection with cytomegalovirus (CMV) has been associated with cardiovascular morbidity in both those with HIV and those without HIV. In a study of 6111 individuals with HIV, of whom 5119 (82 percent) were seropositive for CMV, seropositivity was independently associated with non-AIDS events, including cardiovascular and cerebrovascular diseases [<a href="#rid84">84</a>]. Studies evaluating the pathogenesis of this association have suggested a potential role in atherogenesis. In a study of 93 patients with HIV (91 percent men and 94 percent on ART), greater CD4 and CD8 T-cell responses against CMV were independently associated with increased carotid IMT [<a href="#rid85">85</a>]. In a separate study of 601 women with HIV and positive CMV immunoglobulin G (IgG) serology, higher levels of CMV IgG were independently associated with carotid artery stiffness but not carotid IMT as measured by carotid ultrasound [<a href="#rid86">86</a>]. No such association was seen in 90 uninfected controls matched for age and race. That study also found that CMV IgG levels were associated with carotid artery lesions only among patients with HIV who had viral suppression on ART, not those who were untreated or continued to be viremic despite ART. This suggests that decreased HIV viral replication may be mediating the relationship between an enhanced immune response against CMV and vascular disease. In contrast, a recent cross-sectional analysis from the REPRIEVE cohort (a predominantly virologically suppressed cohort) found no association between CMV IgG titer and presence of plaque, coronary artery calcium (CAC) score &gt;0, or the presence of vulnerable plaque [<a href="#rid87">87</a>].</p><p>Other viruses that have been implicated in the development of subclinical cardiovascular disease in patients with HIV include herpes simplex virus 2 (HSV-2) [<a href="#rid88">88</a>]. Coinfection with Hepatitis C virus (HCV) has been linked to endothelial dysfunction [<a href="#rid89">89</a>] and modulates known risk factors for cardiovascular disease in patients with HIV, but it is not clear if HCV increases their risk of myocardial infarction [<a href="#rid90">90-92</a>]. (See  <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV", section on 'Hepatitis C virus infection'</a>.)</p><p class="headingAnchor" id="H10000634"><span class="h3">Vitamin D</span><span class="headingEndMark"> — </span>Vitamin D deficiency in patients with HIV has been linked to indirect markers of subclinical atherosclerotic cardiovascular disease, including carotid IMT and brachial artery flow-mediated dilation [<a href="#rid51">51,93-95</a>].</p><p>However, it is unclear whether replacing vitamin D improves cardiovascular outcomes. Studies evaluating the effect of vitamin D supplementation on indirect measures of atherosclerosis (eg, brachial artery flow-mediated dilation and carotid IMT) are conflicting [<a href="#rid96">96,97</a>]. In a trial of 45 adults with HIV and viral suppression on ART who had vitamin D levels &lt;20 ng/mL, there was no significant change in brachial artery flow-mediated dilation at 12 weeks in the 30 patients randomly assigned to daily supplementation with 4000 international units <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">cholecalciferol</a> or in the 15 patients assigned to placebo [<a href="#rid96">96</a>]. Furthermore, other than a small decrease in the IL-6 level in those taking supplementation, there were no differences between the two groups in other markers of endothelial dysfunction, coagulation function, or inflammation. Of note, the patients in the supplementation group experienced a mere 5 ng/mL increase in the vitamin D level. In another small randomized trial in HIV-positive youth, standard-dose vitamin D supplementation decreased carotid IMT over 24 months, whereas high-dose supplementation increased it [<a href="#rid97">97</a>].</p><p class="headingAnchor" id="H1454065329"><span class="h1">EPIGENETIC MODIFICATION</span><span class="headingEndMark"> — </span>Epigenetic modification (chemical alteration to DNA that does not affect the sequence but may change the expression or regulation of genes) is a potential predictor of risk for chronic diseases, including cardiovascular disease [<a href="#rid98">98</a>]. Studies in HIV pathogenesis suggest that chronic HIV infection can lead to epigenetic modification [<a href="#rid99">99</a>]. Subsequent data from several cohort studies among individuals with HIV have identified markers of DNA methylation consistent with accelerated aging [<a href="#rid100">100</a>] and have linked these changes to risk factors for future cardiovascular disease [<a href="#rid101">101,102</a>]. Continued research into these measures for predicting future risk appears promising. (See  <a class="medical medical_review" href="/z/d/html/14601.html" rel="external">"Principles of epigenetics"</a>.)</p><p class="headingAnchor" id="H1592992"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subclinical atherosclerosis </strong>– Studies that rely on measures of subclinical atherosclerosis, such as carotid intima media thickness (IMT) and coronary artery plaque on imaging, suggest an increased prevalence of cardiovascular disease in patients with HIV, and cardiovascular disease has emerged as an important cause of morbidity and mortality in this population. (See <a class="local">'Subclinical atherosclerosis'</a> above and  <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis of vascular disease </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cellular activation and endothelial dysfunction </strong>– HIV infection is associated with increased soluble and cellular markers of inflammation, endothelial dysfunction, and altered coagulation, all of which have been shown to contribute to cardiovascular disease. The strongest associations have been between measures of innate immune activation and cardiovascular disease. The effect of antiretroviral therapy (ART) on these markers is less clear. (See <a class="local">'Inflammation'</a> above and <a class="local">'Cellular activation'</a> above and <a class="local">'Endothelial dysfunction'</a> above and <a class="local">'Abnormalities of coagulation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Traditional risk factors </strong>– Traditional cardiovascular risk factors, such as hypertension, diabetes mellitus, dyslipidemia, and cigarette smoking, also contribute substantially to the pathogenesis of cardiovascular disease in patients with HIV. Their prevalence among patients with HIV is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV", section on 'Traditional risk factors'</a>.)</p><p></p><p class="headingAnchor" id="H2135742802"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Abstracts from the 2022 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med 2022; 30:3.</a></li><li><a class="nounderline abstract_t">Althoff KN, Gebo KA, Moore RD, et al. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV 2019; 6:e93.</a></li><li><a class="nounderline abstract_t">Bots ML, Baldassarre D, Simon A, et al. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur Heart J 2007; 28:398.</a></li><li><a class="nounderline abstract_t">Hsue PY, Scherzer R, Hunt PW, et al. Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. J Am Heart Assoc 2012; 1.</a></li><li><a class="nounderline abstract_t">Pereyra F, Lo J, Triant VA, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 2012; 26:2409.</a></li><li><a class="nounderline abstract_t">Groenendijk AL, Vos WAJW, Dos Santos JC, et al. Non-AIDS Events in Individuals With Spontaneous Control of HIV-1: A Systematic Review. J Acquir Immune Defic Syndr 2022; 91:242.</a></li><li><a class="nounderline abstract_t">Hulten E, Mitchell J, Scally J, et al. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart 2009; 95:1826.</a></li><li><a class="nounderline abstract_t">Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23:1841.</a></li><li><a class="nounderline abstract_t">Mercié P, Thiébaut R, Aurillac-Lavignolle V, et al. Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. HIV Med 2005; 6:380.</a></li><li><a class="nounderline abstract_t">Currier JS, Kendall MA, Henry WK, et al. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 2007; 21:1137.</a></li><li><a class="nounderline abstract_t">Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008; 22:1615.</a></li><li><a class="nounderline abstract_t">Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23:1059.</a></li><li><a class="nounderline abstract_t">Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603.</a></li><li><a class="nounderline abstract_t">Bongiovanni M, Casana M, Cicconi P, et al. Predictive factors of vascular intima media thickness in HIV-positive subjects. J Antimicrob Chemother 2008; 61:195.</a></li><li><a class="nounderline abstract_t">Fitch KV, Looby SE, Rope A, et al. Effects of aging and smoking on carotid intima-media thickness in HIV-infection. AIDS 2013; 27:49.</a></li><li><a class="nounderline abstract_t">Hanna DB, Post WS, Deal JA, et al. HIV Infection Is Associated With Progression of Subclinical Carotid Atherosclerosis. Clin Infect Dis 2015; 61:640.</a></li><li><a class="nounderline abstract_t">Hanna DB, Guo M, Bůžková P, et al. HIV Infection and Carotid Artery Intima-media Thickness: Pooled Analyses Across 5 Cohorts of the NHLBI HIV-CVD Collaborative. Clin Infect Dis 2016; 63:249.</a></li><li><a class="nounderline abstract_t">Stein JH, Ribaudo HJ, Hodis HN, et al. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS 2015; 29:1775.</a></li><li><a class="nounderline abstract_t">Calza L, Borderi M, Colangeli V, et al. No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up. Infect Dis (Lond) 2020; 52:249.</a></li><li><a class="nounderline abstract_t">Tarr PE, Ledergerber B, Calmy A, et al. Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons. Eur Heart J 2018; 39:2147.</a></li><li><a class="nounderline abstract_t">Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010; 24:243.</a></li><li><a class="nounderline abstract_t">Fitch KV, Lo J, Abbara S, et al. Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters. J Acquir Immune Defic Syndr 2010; 55:495.</a></li><li><a class="nounderline abstract_t">Fitch KV, Srinivasa S, Abbara S, et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013; 208:1737.</a></li><li><a class="nounderline abstract_t">Post WS, Budoff M, Kingsley L, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med 2014; 160:458.</a></li><li><a class="nounderline abstract_t">Kingsley LA, Deal J, Jacobson L, et al. Incidence and progression of coronary artery calcium in HIV-infected and HIV-uninfected men. AIDS 2015; 29:2427.</a></li><li><a class="nounderline abstract_t">Lo J, Lu MT, Ihenachor EJ, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV 2015; 2:e52.</a></li><li><a class="nounderline abstract_t">Hoffmann U, Lu MT, Foldyna B, et al. Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. JAMA Netw Open 2021; 4:e2114923.</a></li><li><a class="nounderline abstract_t">Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA 2012; 308:379.</a></li><li><a class="nounderline abstract_t">Reingold J, Wanke C, Kotler D, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008; 48:142.</a></li><li><a class="nounderline abstract_t">Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010; 55:316.</a></li><li><a class="nounderline abstract_t">Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51:268.</a></li><li><a class="nounderline abstract_t">Aslangul E, Fellahi S, Assoumou LK, et al. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. AIDS 2011; 25:1128.</a></li><li><a class="nounderline abstract_t">Arildsen H, Sørensen KE, Ingerslev JM, et al. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med 2013; 14:1.</a></li><li><a class="nounderline abstract_t">Hileman CO, Wohl DA, Tisch DJ, et al. Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens. AIDS Res Hum Retroviruses 2012; 28:1561.</a></li><li><a class="nounderline abstract_t">Martínez E, D'Albuquerque PM, Llibre JM, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012; 26:2315.</a></li><li><a class="nounderline abstract_t">Hileman CO, Kinley B, Scharen-Guivel V, et al. Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals. J Infect Dis 2015; 212:345.</a></li><li><a class="nounderline abstract_t">McComsey GA, Kitch D, Daar ES, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012; 26:1371.</a></li><li><a class="nounderline abstract_t">Bastard JP, Fellahi S, Couffignal C, et al. Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity. J Antimicrob Chemother 2015; 70:1816.</a></li><li><a class="nounderline abstract_t">Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012; 205 Suppl 3:S375.</a></li><li><a class="nounderline abstract_t">Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012; 55:126.</a></li><li><a class="nounderline abstract_t">Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.</a></li><li><a class="nounderline abstract_t">Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7:e44454.</a></li><li><a class="nounderline abstract_t">Baker J, Quick H, Hullsiek KH, et al. Interleukin-6 and d-dimer levels are associated with vascular dysfunction in patients with untreated HIV infection. HIV Med 2010; 11:608.</a></li><li><a class="nounderline abstract_t">Borges ÁH, O'Connor JL, Phillips AN, et al. Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. J Infect Dis 2016; 214:408.</a></li><li><a class="nounderline abstract_t">Longenecker CT, Funderburg NT, Jiang Y, et al. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med 2013; 14:385.</a></li><li><a class="nounderline abstract_t">Merlini E, Luzi K, Suardi E, et al. T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis. PLoS One 2012; 7:e46073.</a></li><li><a class="nounderline abstract_t">Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011; 203:452.</a></li><li><a class="nounderline abstract_t">Kaplan RC, Sinclair E, Landay AL, et al. T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis 2011; 217:207.</a></li><li><a class="nounderline abstract_t">Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204:1227.</a></li><li><a class="nounderline abstract_t">Kelesidis T, Kendall MA, Yang OO, et al. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206:1558.</a></li><li><a class="nounderline abstract_t">Ross AC, Judd S, Kumari M, et al. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals. Antivir Ther 2011; 16:555.</a></li><li><a class="nounderline abstract_t">Hearps AC, Maisa A, Cheng WJ, et al. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 2012; 26:843.</a></li><li><a class="nounderline abstract_t">Baker JV, Hullsiek KH, Singh A, et al. Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. AIDS 2014; 28:831.</a></li><li><a class="nounderline abstract_t">McKibben RA, Margolick JB, Grinspoon S, et al. Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection. J Infect Dis 2015; 211:1219.</a></li><li><a class="nounderline abstract_t">Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52:569.</a></li><li><a class="nounderline abstract_t">Murphy R, Costagliola D. Increased cardiovascular risk in HIV infection: drugs, virus and immunity. AIDS 2008; 22:1625.</a></li><li><a class="nounderline abstract_t">Baker JV, Duprez D, Rapkin J, et al. Untreated HIV infection and large and small artery elasticity. J Acquir Immune Defic Syndr 2009; 52:25.</a></li><li><a class="nounderline abstract_t">van Wijk JP, de Koning EJ, Cabezas MC, et al. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol 2006; 47:1117.</a></li><li><a class="nounderline abstract_t">Schillaci G, De Socio GV, Pirro M, et al. Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection. Arterioscler Thromb Vasc Biol 2005; 25:2381.</a></li><li><a class="nounderline abstract_t">Shankar SS, Dubé MP, Gorski JC, et al. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 2005; 150:933.</a></li><li><a class="nounderline abstract_t">Dubé MP, Shen C, Greenwald M, Mather KJ. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin Infect Dis 2008; 47:567.</a></li><li><a class="nounderline abstract_t">Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009; 23:2021.</a></li><li><a class="nounderline abstract_t">Graham SM, Rajwans N, Jaoko W, et al. Endothelial activation biomarkers increase after HIV-1 acquisition: plasma vascular cell adhesion molecule-1 predicts disease progression. AIDS 2013; 27:1803.</a></li><li><a class="nounderline abstract_t">Francisci D, Giannini S, Baldelli F, et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 2009; 23:589.</a></li><li><a class="nounderline abstract_t">Baker JV, Neuhaus J, Duprez D, et al. HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction. J Acquir Immune Defic Syndr 2012; 60:128.</a></li><li><a class="nounderline abstract_t">de Gaetano Donati K, Rabagliati R, Tumbarello M, et al. Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. AIDS 2003; 17:765.</a></li><li><a class="nounderline abstract_t">Chai H, Yang H, Yan S, et al. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J Acquir Immune Defic Syndr 2005; 40:12.</a></li><li><a class="nounderline abstract_t">Fu W, Chai H, Yao Q, Chen C. Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression. J Acquir Immune Defic Syndr 2005; 39:152.</a></li><li><a class="nounderline abstract_t">de Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect Dis 2004; 4:213.</a></li><li><a class="nounderline abstract_t">Panigrahi S, Freeman ML, Funderburg NT, et al. SIV/SHIV Infection Triggers Vascular Inflammation, Diminished Expression of Krüppel-like Factor 2 and Endothelial Dysfunction. J Infect Dis 2016; 213:1419.</a></li><li><a class="nounderline abstract_t">Baliga RS, Chaves AA, Jing L, et al. AIDS-related vasculopathy: evidence for oxidative and inflammatory pathways in murine and human AIDS. Am J Physiol Heart Circ Physiol 2005; 289:H1373.</a></li><li><a class="nounderline abstract_t">Martin S, Tesse A, Hugel B, et al. Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation 2004; 109:1653.</a></li><li><a class="nounderline abstract_t">Schecter AD, Berman AB, Yi L, et al. HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci U S A 2001; 98:10142.</a></li><li><a class="nounderline abstract_t">Paladugu R, Fu W, Conklin BS, et al. Hiv Tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg 2003; 38:549.</a></li><li><a class="nounderline abstract_t">Seigneur M, Constans J, Blann A, et al. Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Thromb Haemost 1997; 77:646.</a></li><li><a class="nounderline abstract_t">Blann AD, Seigneur M, Constans J, et al. Soluble P-selectin, thrombocytopenia and von Willebrand factor in HIV infected patients. Thromb Haemost 1997; 77:1221.</a></li><li><a class="nounderline abstract_t">Perkins MV, Joseph SB, Dittmer DP, Mackman N. Cardiovascular Disease and Thrombosis in HIV Infection. Arterioscler Thromb Vasc Biol 2023; 43:175.</a></li><li><a class="nounderline abstract_t">Karmochkine M, Ankri A, Calvez V, et al. Plasma hypercoagulability is correlated to plasma HIV load. Thromb Haemost 1998; 80:208.</a></li><li><a class="nounderline abstract_t">Ford ES, Greenwald JH, Richterman AG, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010; 24:1509.</a></li><li><a class="nounderline abstract_t">Hsue PY, Scherzer R, Grunfeld C, et al. HIV infection is associated with decreased thrombin generation. Clin Infect Dis 2012; 54:1196.</a></li><li><a class="nounderline abstract_t">Madden E, Lee G, Kotler DP, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS 2008; 22:707.</a></li><li><a class="nounderline abstract_t">Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 2010; 115:161.</a></li><li><a class="nounderline abstract_t">Barska K, Kwiatkowska W, Knysz B, et al. The role of the tissue factor and its inhibitor in the development of subclinical atherosclerosis in people living with HIV. PLoS One 2017; 12:e0181533.</a></li><li><a class="nounderline abstract_t">Lichtner M, Cicconi P, Vita S, et al. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. J Infect Dis 2015; 211:178.</a></li><li><a class="nounderline abstract_t">Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20:2275.</a></li><li><a class="nounderline abstract_t">Parrinello CM, Sinclair E, Landay AL, et al. Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. J Infect Dis 2012; 205:1788.</a></li><li><a class="nounderline abstract_t">Schnittman SR, Lu MT, Mayrhofer T, et al. Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV). Clin Infect Dis 2023; 76:e613.</a></li><li><a class="nounderline abstract_t">Hechter RC, Budoff M, Hodis HN, et al. Herpes simplex virus type 2 (HSV-2) as a coronary atherosclerosis risk factor in HIV-infected men: multicenter AIDS cohort study. Atherosclerosis 2012; 223:433.</a></li><li><a class="nounderline abstract_t">de Castro IF, Micheloud D, Berenguer J, et al. Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients. AIDS 2010; 24:2059.</a></li><li><a class="nounderline abstract_t">Freiberg MS, Chang CC, Skanderson M, et al. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes 2011; 4:425.</a></li><li><a class="nounderline abstract_t">Bedimo R, Westfall AO, Mugavero M, et al. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 2010; 11:462.</a></li><li><a class="nounderline abstract_t">Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group, Weber R, Sabin C, et al. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther 2010; 15:1077.</a></li><li><a class="nounderline abstract_t">Lai H, Gerstenblith G, Fishman EK, et al. Vitamin D deficiency is associated with silent coronary artery disease in cardiovascularly asymptomatic African Americans with HIV infection. Clin Infect Dis 2012; 54:1747.</a></li><li><a class="nounderline abstract_t">Choi AI, Lo JC, Mulligan K, et al. Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons. Clin Infect Dis 2011; 52:941.</a></li><li><a class="nounderline abstract_t">Shikuma CM, Seto T, Liang CY, et al. Vitamin D levels and markers of arterial dysfunction in HIV. AIDS Res Hum Retroviruses 2012; 28:793.</a></li><li><a class="nounderline abstract_t">Longenecker CT, Hileman CO, Carman TL, et al. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther 2012; 17:613.</a></li><li><a class="nounderline abstract_t">Eckard AR, Raggi P, O'Riordan MA, et al. Effects of vitamin D supplementation on carotid intima-media thickness in HIV-infected youth. Virulence 2018; 9:294.</a></li><li><a class="nounderline abstract_t">Roetker NS, Pankow JS, Bressler J, et al. Prospective Study of Epigenetic Age Acceleration and Incidence of Cardiovascular Disease Outcomes in the ARIC Study (Atherosclerosis Risk in Communities). Circ Genom Precis Med 2018; 11:e001937.</a></li><li><a class="nounderline abstract_t">Maricato JT, Furtado MN, Takenaka MC, et al. Epigenetic modulations in activated cells early after HIV-1 infection and their possible functional consequences. PLoS One 2015; 10:e0119234.</a></li><li><a class="nounderline abstract_t">Ebner BF, Chueng T, Martinez CA. Epigenetics, HIV, and Cardiovascular Disease Risk. Curr Probl Cardiol 2021; 46:100615.</a></li><li><a class="nounderline abstract_t">Huang RC, Lillycrop KA, Beilin LJ, et al. Epigenetic Age Acceleration in Adolescence Associates With BMI, Inflammation, and Risk Score for Middle Age Cardiovascular Disease. J Clin Endocrinol Metab 2019; 104:3012.</a></li><li><a class="nounderline abstract_t">Horvath S, Levine AJ. HIV-1 Infection Accelerates Age According to the Epigenetic Clock. J Infect Dis 2015; 212:1563.</a></li></ol></div><div id="topicVersionRevision">Topic 83686 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35298110" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Abstracts from the 2022 Conference on Retroviruses and Opportunistic Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30683625" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17277033" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23130122" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23032411" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35969465" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Non-AIDS Events in Individuals With Spontaneous Control of HIV-1: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19632982" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19455012" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16268819" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502724" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18670221" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19390417" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15023877" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17999980" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Predictive factors of vascular intima media thickness in HIV-positive subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22874518" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effects of aging and smoking on carotid intima-media thickness in HIV-infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25904369" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : HIV Infection Is Associated With Progression of Subclinical Carotid Atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27118787" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : HIV Infection and Carotid Artery Intima-media Thickness: Pooled Analyses Across 5 Cohorts of the NHLBI HIV-CVD Collaborative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26372383" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31876437" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29590332" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996940" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20720497" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24041790" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687069" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Associations between HIV infection and subclinical coronary atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26558542" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Incidence and progression of coronary artery calcium in HIV-infected and HIV-uninfected men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26424461" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34185068" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22820791" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Arterial inflammation in patients with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18344877" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20581689" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19387353" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Association of C-reactive protein and HIV infection with acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422984" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22639788" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22463776" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23018438" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25583168" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22546988" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25733587" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22577211" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Immunologic basis of cardiovascular disease in HIV-infected adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22534147" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18942885" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22970224" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Inflammation, coagulation and cardiovascular disease in HIV-infected individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20456504" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Interleukin-6 and d-dimer levels are associated with vascular dysfunction in patients with untreated HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27132283" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23332012" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23029393" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21220772" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21492857" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : T cell activation predicts carotid artery stiffness among HIV-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21917896" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23066162" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21685543" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22313961" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24370480" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25362192" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18687253" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18670222" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Increased cardiovascular risk in HIV infection: drugs, virus and immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19731451" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Untreated HIV infection and large and small artery elasticity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16545639" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16123321" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16290967" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Indinavir impairs endothelial function in healthy HIV-negative men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18636958" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19542863" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23807276" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Endothelial activation biomarkers increase after HIV-1 acquisition: plasma vascular cell adhesion molecule-1 predicts disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19177019" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22421746" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12646805" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16123675" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15905730" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15050939" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : HIV infection, HAART, and endothelial adhesion molecules: current perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26671887" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : SIV/SHIV Infection Triggers Vascular Inflammation, Diminished Expression of Krüppel-like Factor 2 and Endothelial Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15923317" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : AIDS-related vasculopathy: evidence for oxidative and inflammatory pathways in murine and human AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15023873" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11504923" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : HIV envelope gp120 activates human arterial smooth muscle cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12947275" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Hiv Tat protein causes endothelial dysfunction in porcine coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9134636" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Soluble adhesion molecules and endothelial cell damage in HIV infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9241764" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Soluble P-selectin, thrombocytopenia and von Willebrand factor in HIV infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36453273" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cardiovascular Disease and Thrombosis in HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9684818" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Plasma hypercoagulability is correlated to plasma HIV load.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20505494" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22438347" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : HIV infection is associated with decreased thrombin generation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18356600" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Association of antiretroviral therapy with fibrinogen levels in HIV-infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19828697" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28749986" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The role of the tissue factor and its inhibitor in the development of subclinical atherosclerosis in people living with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25081936" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17117013" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22492856" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35975297" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22472456" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Herpes simplex virus type 2 (HSV-2) as a coronary atherosclerosis risk factor in HIV-infected men: multicenter AIDS cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20616694" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21712519" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20163481" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21149914" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22423137" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Vitamin D deficiency is associated with silent coronary artery disease in cardiovascularly asymptomatic African Americans with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21273298" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21978287" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Vitamin D levels and markers of arterial dysfunction in HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22293363" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28891732" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Effects of vitamin D supplementation on carotid intima-media thickness in HIV-infected youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29555670" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Prospective Study of Epigenetic Age Acceleration and Incidence of Cardiovascular Disease Outcomes in the ARIC Study (Atherosclerosis Risk in Communities).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25875202" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Epigenetic modulations in activated cells early after HIV-1 infection and their possible functional consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32507271" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Epigenetics, HIV, and Cardiovascular Disease Risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30785999" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Epigenetic Age Acceleration in Adolescence Associates With BMI, Inflammation, and Risk Score for Middle Age Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25969563" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : HIV-1 Infection Accelerates Age According to the Epigenetic Clock.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
